{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:26:42Z","timestamp":1791919602916,"version":"4.3.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"JSPS KAKENHI","award":["24K12434"],"award-info":[{"award-number":["24K12434"]}]},{"name":"JSPS KAKENHI","award":["24K02576"],"award-info":[{"award-number":["24K02576"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s10147-024-02575-3","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T09:04:47Z","timestamp":1719911087000},"page":"1088-1095","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Urological cancer statistics on incidence from 1975 to 2019 and mortality from 1958 to 2022 in Japan"],"prefix":"10.1007","volume":"29","author":[{"given":"Takeshi","family":"Sasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Higashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"issue":"1","key":"2575_CR1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.eururo.2022.11.023","volume":"84","author":"EJ Schafer","year":"2023","unstructured":"Schafer EJ, Jemal A, Wiese D et al (2023) Disparities and trends in genitourinary cancer incidence and mortality in the USA. Eur Urol 84(1):117\u2013126. https:\/\/doi.org\/10.1016\/j.eururo.2022.11.023","journal-title":"Eur Urol"},{"key":"2575_CR2","doi-asserted-by":"publisher","first-page":"1119374","DOI":"10.3389\/fpubh.2023.1119374","volume":"11","author":"YQ Tian","year":"2023","unstructured":"Tian YQ, Yang JC, Hu JJ et al (2023) Trends and risk factors of global incidence, mortality, and disability of genitourinary cancers from 1990 to 2019: systematic analysis for the global burden of disease study 2019. Front Public Health 11:1119374. https:\/\/doi.org\/10.3389\/fpubh.2023.1119374","journal-title":"Front Public Health"},{"key":"2575_CR3","doi-asserted-by":"publisher","unstructured":"Giona S (2021) The epidemiology of prostate cancer. In: Bott SRJ, Ng KL (eds) Prostate cancer. Brisbane (AU). https:\/\/doi.org\/10.36255\/exonpublications.prostatecancer.epidemiology.2021","DOI":"10.36255\/exonpublications.prostatecancer.epidemiology.2021"},{"issue":"9","key":"2575_CR4","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1002\/cncr.32733","volume":"126","author":"Z Zhai","year":"2020","unstructured":"Zhai Z, Zheng Y, Li N et al (2020) Incidence and disease burden of prostate cancer from 1990 to 2017: results from the global burden of disease study 2017. Cancer 126(9):1969\u20131978. https:\/\/doi.org\/10.1002\/cncr.32733","journal-title":"Cancer"},{"issue":"1","key":"2575_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s40779-021-00354-z","volume":"8","author":"H Zi","year":"2021","unstructured":"Zi H, He SH, Leng XY et al (2021) Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990\u20132019. Mil Med Res 8(1):60. https:\/\/doi.org\/10.1186\/s40779-021-00354-z","journal-title":"Mil Med Res"},{"issue":"1","key":"2575_CR6","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.euf.2021.01.006","volume":"8","author":"Y Zhan","year":"2022","unstructured":"Zhan Y, Pan C, Zhao Y et al (2022) Systematic analysis of the global, regional and national burden of kidney cancer from 1990 to 2017: results from the global burden of disease study 2017. Eur Urol Focus 8(1):302\u2013319. https:\/\/doi.org\/10.1016\/j.euf.2021.01.006","journal-title":"Eur Urol Focus"},{"issue":"9","key":"2575_CR7","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/jjco\/hyh100","volume":"34","author":"K Kamo","year":"2004","unstructured":"Kamo K, Sobue T (2004) Cancer statistics digest. Mortality trend of prostate, breast, uterus, ovary, bladder and \u201ckidney and other urinary tract\u201d cancer in Japan by birth cohort. Jpn J Clin Oncol 34(9):561\u2013563. https:\/\/doi.org\/10.1093\/jjco\/hyh100","journal-title":"Jpn J Clin Oncol"},{"issue":"11","key":"2575_CR8","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1093\/jjco\/hyw158","volume":"46","author":"K Saika","year":"2016","unstructured":"Saika K, Machii R (2016) Incidence rate for prostate cancer in Japanese in Japan and in the United States from the cancer incidence in five continents. Jpn J Clin Oncol 46(11):1074. https:\/\/doi.org\/10.1093\/jjco\/hyw158","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"2575_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/jjco\/hyv123","volume":"46","author":"H Akaza","year":"2016","unstructured":"Akaza H (2016) Urologic cancer in Japan: role of Japan at the frontier of issues in Asia. Jpn J Clin Oncol 46(1):23\u201330. https:\/\/doi.org\/10.1093\/jjco\/hyv123","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"2575_CR10","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1158\/1055-9965.EPI-19-1228","volume":"29","author":"E Saito","year":"2020","unstructured":"Saito E, Hori M, Matsuda T et al (2020) Long-term trends in prostate cancer incidence by stage at diagnosis in japan using the multiple imputation approach, 1993\u20132014. Cancer Epidemiol Biomarkers Prev 29(6):1222\u20131228. https:\/\/doi.org\/10.1158\/1055-9965.EPI-19-1228","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"19","key":"2575_CR11","doi-asserted-by":"publisher","first-page":"7330","DOI":"10.1002\/cam4.3382","volume":"9","author":"J Aoe","year":"2020","unstructured":"Aoe J, Ito Y, Fukui K et al (2020) Long-term trends in sex difference in bladder cancer survival 1975\u20132009: a population-based study in Osaka. Japan Cancer Med 9(19):7330\u20137340. https:\/\/doi.org\/10.1002\/cam4.3382","journal-title":"Japan Cancer Med"},{"key":"2575_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-024-02473-8","author":"H Nakai","year":"2024","unstructured":"Nakai H, Higashi T, Kakuwa T et al (2024) Trends in gynecologic cancer in Japan: incidence from 1980 to 2019 and mortality from 1981 to 2021. Int J Clin Oncol. https:\/\/doi.org\/10.1007\/s10147-024-02473-8","journal-title":"Int J Clin Oncol"},{"issue":"Suppl 1","key":"2575_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/hec.3986","volume":"30","author":"M Kasajima","year":"2021","unstructured":"Kasajima M, Hashimoto H et al (2021) Future projection of the health and functional status of older people in Japan: a multistate transition microsimulation model with repeated cross-sectional data. Health Econ 30(Suppl 1):30\u201351. https:\/\/doi.org\/10.1002\/hec.3986","journal-title":"Health Econ"},{"issue":"1","key":"2575_CR14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","volume":"71","author":"S Antoni","year":"2017","unstructured":"Antoni S, Ferlay J, Soerjomataram I et al (2017) Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 71(1):96\u2013108. https:\/\/doi.org\/10.1016\/j.eururo.2016.06.010","journal-title":"Eur Urol"},{"issue":"5","key":"2575_CR15","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/nrurol.2010.46","volume":"7","author":"WH Chow","year":"2010","unstructured":"Chow WH, Dong LM, Devesa SS (2010) Epidemiology and risk factors for kidney cancer. Nat Rev Urol 7(5):245\u2013257. https:\/\/doi.org\/10.1038\/nrurol.2010.46","journal-title":"Nat Rev Urol"},{"issue":"6","key":"2575_CR16","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41568-019-0142-8","volume":"19","author":"S Srivastava","year":"2019","unstructured":"Srivastava S, Koay EJ, Borowsky AD et al (2019) Cancer overdiagnosis: a biological challenge and clinical dilemma. Nat Rev Cancer 19(6):349\u2013358. https:\/\/doi.org\/10.1038\/s41568-019-0142-8","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"2575_CR17","doi-asserted-by":"publisher","first-page":"426","DOI":"10.2188\/jea.JE20200416","volume":"31","author":"K Katanoda","year":"2021","unstructured":"Katanoda K, Hori M, Saito E et al (2021) Updated trends in cancer in Japan: incidence in 1985\u20132015 and mortality in 1958\u20132018-a sign of decrease in cancer incidence. J Epidemiol 31(7):426\u2013450. https:\/\/doi.org\/10.2188\/jea.JE20200416","journal-title":"J Epidemiol"},{"issue":"5","key":"2575_CR18","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2471\/BLT.12.108092","volume":"91","author":"I Funatogawa","year":"2013","unstructured":"Funatogawa I, Funatogawa T, Yano E (2013) Trends in smoking and lung cancer mortality in Japan, by birth cohort, 1949\u20132010. Bull World Health Organ 91(5):332\u2013340. https:\/\/doi.org\/10.2471\/BLT.12.108092","journal-title":"Bull World Health Organ"},{"key":"2575_CR19","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2020072","volume":"42","author":"T Okui","year":"2020","unstructured":"Okui T (2020) An age-period-cohort analysis of the difference in smoking prevalence between urban and non-urban areas in Japan (2004\u20132019). Epidemiol Health 42:e2020072. https:\/\/doi.org\/10.4178\/epih.e2020072","journal-title":"Epidemiol Health"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02575-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02575-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02575-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T05:31:24Z","timestamp":1721885484000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02575-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2575"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02575-3","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,2]]},"assertion":[{"value":"22 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective study was performed using publicly available statistical data (, Accessed February 4, 2024) on malignant tumors. The requirement for approval from the institutional review board was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}